PD 128042
PD 128042 structure
|
Common Name | PD 128042 | ||
|---|---|---|---|---|
| CAS Number | 114289-47-3 | Molecular Weight | 393.56000 | |
| Density | 1.002g/cm3 | Boiling Point | 504.7ºC at 760mmHg | |
| Molecular Formula | C23H39NO4 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 259ºC | |
Use of PD 128042PD 128042 (CI 976) is a potent, orally active, and selective inhibitor of ACAT (acyl coenzyme A:cholesterol acyltransferase) with an IC50s of 73 nM. PD 128042 is also a potent LPAT (lysophospholipid acyltransferase) inhibitor. PD 128042 inhibits Golgi-associated LPAT activity (IC50=15 μM). PD 128042 inhibits multiple membrane trafficking steps, including ones found in the endocytic and secretory pathway[1][2][3]. |
| Name | 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide |
|---|---|
| Synonym | More Synonyms |
| Description | PD 128042 (CI 976) is a potent, orally active, and selective inhibitor of ACAT (acyl coenzyme A:cholesterol acyltransferase) with an IC50s of 73 nM. PD 128042 is also a potent LPAT (lysophospholipid acyltransferase) inhibitor. PD 128042 inhibits Golgi-associated LPAT activity (IC50=15 μM). PD 128042 inhibits multiple membrane trafficking steps, including ones found in the endocytic and secretory pathway[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vivo | PD 128042 (CI 976) (10-30 mg/kg; gavage, in the chronic cholesterol-fed rat model) decreases non-high density lipoprotein (HDL)-cholesterol and increases HDL-cholesterol in rats with pre-established dyslipidemia[4]. |
| References |
| Density | 1.002g/cm3 |
|---|---|
| Boiling Point | 504.7ºC at 760mmHg |
| Molecular Formula | C23H39NO4 |
| Molecular Weight | 393.56000 |
| Flash Point | 259ºC |
| Exact Mass | 393.28800 |
| PSA | 56.79000 |
| LogP | 6.28090 |
| Vapour Pressure | 2.59E-10mmHg at 25°C |
| Index of Refraction | 1.503 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
cPLA2α and EHD1 interact and regulate the vesiculation of cholesterol-rich, GPI-anchored, protein-containing endosomes.
Mol. Biol. Cell 23(10) , 1874-88, (2012) The lipid modifier phospholipase A2 catalyzes the hydrolysis of phospholipids to inverted-cone-shaped lysophospholipids that contribute to membrane curvature and/or tubulation. Conflicting findings ex... |
|
|
Use of acyltransferase inhibitors to block vesicular traffic between the ER and Golgi complex.
Meth. Enzymol. 404 , 115-25, (2005) This article describes the use of acyltransferase inhibitors as probes for studying the potential role of lysophospholipid acyltransferases (LPAT) in intracellular membrane trafficking in the secretor... |
|
|
A unique lysophospholipid acyltransferase (LPAT) antagonist, CI-976, affects secretory and endocytic membrane trafficking pathways.
J. Cell Sci. 118(Pt 14) , 3061-71, (2005) Previous studies have shown that inhibition of a Golgi-complex-associated lysophospholipid acyltransferase (LPAT) activity by the drug CI-976 stimulates Golgi tubule formation and subsequent redistrib... |
| CI 976 |
| 2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide |
| C23H39NO4 |